Yr Athro Richard Darley

2023

• Rastogi, N. et al. 2023. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia. Leukemia 37, pp. 276-287. (10.1038/s41375-022-01801-z)
• Wagstaff, M. et al. 2023. Crosstalk between β-catenin and WT1 signalling activity in acute myeloid leukemia [Letters to the Editor]. Haematologica 108(1) (10.3324/haematol.2021.280294)

2022

• Morgan, H. J. et al. 2022. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. Journal of Clinical Investigation 132(21), article number: e150750. (10.1172/JCI150750)
• Menezes, A. C. et al. 2022. Increased expression of RUNX3 inhibits normal human myeloid development. Leukemia 36, pp. 1769-1780. (10.1038/s41375-022-01577-2)
• Nicholson, R. et al. 2022. Protein kinase C epsilon overexpression is associated with poor patient outcomes in AML and promotes daunorubicin resistance through p-glycoprotein-mediated drug efflux. Frontiers in Oncology 12, article number: 840046. (10.3389/fonc.2022.840046)
• Menezes, A. C. et al. 2022. RUNX3 overexpression inhibits normal human erythroid development. Scientific Reports 12, article number: 1243. (10.1038/s41598-022-05371-z)

2021

• Robinson, A. J., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species in leukemias: maintaining cancer cell proliferation via redox signaling and changing metabolic homeostasis. Oncotarget 12(10), pp. 952-954. (10.18632/oncotarget.27913)
• Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193(1), pp. 155-159. (10.1111/bjh.17125)
• Robinson, A. J., Darley, R. L. and Tonks, A. 2021. Reactive oxygen species and metabolic re-wiring in acute leukemias. In: Piccaluga, P. P. ed. Acute Leukemias. IntechOpen, (10.5772/intechopen.94829)

2020

• Robinson, A. J. et al. 2020. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Research 80(5), pp. 937-949. (10.1158/0008-5472.CAN-19-1920)
• Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34(2), pp. 427-440. (10.1038/s41375-019-0596-4)

2019

• Morgan, R. G. et al. 2019. LEF-1 drives aberrant B-catenin nuclear localization in myeloid leukemia cells. Haematologica 104, pp. 1365-1377., article number: 202846. (10.3324/haematol.2018.202846)
• Wadley, A. J., Morgan, R. G., Darley, R. L., Hole, P. S. and Coles, S. J. 2019. Using flow cytometry to detect and measure intracellular thiol redox status in viable T cells from heterogeneous populations. In: Hancock, J. T. and Conway, M. E. eds. Redox-Mediated Signal Transduction: Methods and Protocols., Vol. 1990. Methods in Molecular Biology New York, NY, USA: Humana Press, pp. 53-70., (10.1007/978-1-4939-9463-2_5)

2015

• Munje, C., Hills, R. K., Whetton, A., Burnett, A. K., Darley, R. L. and Tonks, A. 2015. Cord blood-derived quiescent CD34+ cells are more transcriptionally matched to AML blasts than cytokine-induced normal human hematopoietic CD34+ cells. Gene Expression: International Journal of Molecular and Cellular Science 16(4), pp. 169-175. (10.3727/105221615X14399878166159)
• Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29, pp. 1952-1954. (10.1038/leu.2015.62)
• Agathanggelou, A. et al. 2015. Targeting the ataxia telangiectasia mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants. Haematologica 100(8), pp. 1076-1085. (10.3324/haematol.2014.115170)

2014

• Morgan, R. G., Ridsdale, J., Tonks, A. and Darley, R. L. 2014. Factors affecting the nuclear localization of β-Catenin in normal and malignant tissue. Journal of Cellular Biochemistry 115(8), pp. 1351-1361. (10.1002/jcb.24803)
• Zabkiewicz, J., Pearn, L., Hills, R., Morgan, R. G., Tonks, A., Burnett, A. K. and Darley, R. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99(5), pp. 858-864. (10.3324/haematol.2013.096487)

2013

• Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122(19), pp. 3322-3330. (10.1182/blood-2013-04-491944)
• Morgan, R. G., Pearn, L., Liddiard, K., Pumford, S. L., Burnett, A. K., Tonks, A. and Darley, R. L. 2013. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia 27(2), pp. 336-343. (10.1038/leu.2012.221)

2012

• Daud, S. S. et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120(21), article number: 1281.
• Coles, S., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Man, S. T., Darley, R. L. and Tonks, A. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26(9), pp. 2148-2151. (10.1038/leu.2012.77)
• Coles, S., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Man, S. T., Darley, R. L. and Tonks, A. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26(9), pp. 2146-2148. (10.1038/leu.2012.75)
• Liddiard, K., Burnett, A. K., Darley, R. L. and Tonks, A. 2012. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1 [Letter]. Leukemia 26(1), pp. 177-179. (10.1038/leu.2011.188)

2011

• Coles, S., Man, S. T., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Darley, R. L. and Tonks, A. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135(S1), pp. 178. (10.1111/j.1365-2567.2011.03534.x)
• Coles, S., Wang, E. C. Y., Man, S. T., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25(5), pp. 792-799. (10.1038/leu.2011.1)
• Hole, P. S., Darley, R. L. and Tonks, A. 2011. Do reactive oxygen species play a role in myeloid leukemias?. Blood 117(22), pp. 5816-5826. (10.1182/blood-2011-01-326025)

2010

• Zabkiewicz, J., Pearn, L., Hills, R. K., Morgan, R. G., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116(21), pp. 892-893.
• Morgan, R. G., Pearn, L., Liddiard, K., Hills, R. K., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116(21), article number: 1573.
• Coles, S., Man, S. T., Hills, R. K., Wang, E. C. Y., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116(21), pp. 218-218.
• Liddiard, K., Hills, R. K., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29(13), pp. 2005-2012. (10.1038/onc.2009.462)
• Hole, P. S., Pearn, L., Tonks, A. J., James, P. E., Burnett, A. K., Darley, R. L. and Tonks, A. 2010. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 115(6), pp. 1238-1246. (10.1182/blood-2009-06-222869)

2009

• Yang, J., Darley, R. L., Hallett, M. B. and Evans, W. H. 2009. Low connexin channel-dependent intercellular communication in human adult hematopoietic progenitor/stem cells: Probing mechanisms of autologous stem cell therapy. Cell Communication and Adhesion 16(5-6), pp. 138-145. (10.3109/15419061003653763)
• Dewitt, S., Darley, R. L. and Hallett, M. B. 2009. Translocation or just location? Pseudopodia affect fluorescent signals. Journal of Cell Biology 184(2), pp. 197-203. (10.1083/jcb.200806047)

2007

• Tonks, A., Pearn, L., Musson, M., Gilkes, A. F., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21(12), pp. 2495-2505. (10.1038/sj.leu.2404961)
• Walsby, E. J., Gilkes, A. F., Tonks, A., Darley, R. L. and Mills, K. I. 2007. FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology 139(1), pp. 94-97. (10.1111/j.1365-2141.2007.06756.x)
• Tonks, A., Hills, R. K., White, P. C., Rosie, B., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
• Tonks, A., Hills, R. K., White, P. C., Rosie, B., Mills, K. I., Burnett, A. K. and Darley, R. L. 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21(3), pp. 566-568. (10.1038/sj.leu.2404559)
• Pearn, L., Fisher, J., Burnett, A. K. and Darley, R. L. 2007. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 109(10), pp. 4461-9. (10.1182/blood-2006-09-047217)

2006

• Omidvar, N., Pearn, L., Burnett, A. K. and Darley, R. L. 2006. Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras. Molecular and cellular biology 26(10), pp. 3966-75. (10.1128/MCB.26.10.3966-3975.2006)
• Tonks, A., Pearn, L., Mills, K. I., Burnett, A. K. and Darley, R. L. 2006. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia 20(10), pp. 1883-5. (10.1038/sj.leu.2404364)

2005

• Tonks, A., Tonks, A. J., Pearn, L., Mohamad, Z., Burnett, A. K. and Darley, R. L. 2005. Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnology Progress 21(3), pp. 953-958. (10.1021/bp0500314)

2004

• Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18(7), pp. 1238-1245. (10.1038/sj.leu.2403396)
• Tonks, A. et al. 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18(7), pp. 1238-1245. (10.1038/sj.leu.2403396)

2003

• Tonks, A. et al. 2003. The AML-1 fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101(2), pp. 624-632. (10.1182/blood-2002-06-1732)
• Tonks, A. et al. 2003. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101(2), pp. 624-632. (10.1182/blood-2002-06-1732)

2002

• Darley, R. L. et al. 2002. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 100(12), pp. 4185-92. (10.1182/blood-2002-05-1358)

2000

• McGlynn, A. P., Padua, R. A., Burnett, A. K. and Darley, R. L. 2000. Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells. Leukemia Research 24(1), pp. 47-54. (10.1016/s0145-2126(99)00159-9)
• Darley, R. L., Pearn, L. and Burnett, A. K. 2000. Mutant RAS promotes amplification of primitive human erythroid cells. Blood 96(11), pp. 92A-92A.

1999

• Darley, R. L. and Burnett, A. K. 1999. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Experimental Hematology 27(11), pp. 1599-1608. (10.1016/S0301-472X(99)00100-9)

1998

• Darley, R. L., Hoy, T. G., Robinson, L. and Burnett, A. K. 1998. Mutant N-RAS blocks granulocytic differentiation of human cd34+ cells. British Journal of Haematology 102(1), pp. 289-289. (10.1111/j.1365-2141.1998.tb08997.x)
• Darley, R. L., Hoy, T. G. and Burnett, A. K. 1998. Mutant N-RAS blocks granulocytic differentiation of human CD34(+) cells [Abstract]. British Journal of Haematology 101(S), pp. 22.
• Gallagher, A. P., Burnett, A. K., Bowen, D. T. and Darley, R. L. 1998. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process. Cancer Research 58(9), pp. 2029-2035.

1997

• Darley, R. L., Gallagher, A. P., Bowen, D. T. and Burnett, A. K. 1997. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a PKC-dependent process. Blood 90(10), pp. 202-202.
• Zaker, F., Darley, R. L., Sabah, A. A. and Burnett, A. K. 1997. Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells. Leukemia Research 21(7), pp. 635-640. (10.1016/S0145-2126(97)00022-2)
• Darley, R. L., Hoy, T. G., Baines, P., Padua, R. A. and Burnett, A. K. 1997. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ Cells. Journal of Experimental Medicine 185(7), pp. 1337-1348. (10.1084/jem.185.7.1337)

1996

• Darley, R. L., Baines, P., Hoy, T. G., Padua, R. A. and Burnett, A. K. 1996. Mutant N-RAS alters the developmental potential of human CD34(+) cells in a lineage-specific manner. British Journal of Haematology 93(S2), pp. 597-597.
• Evely, R. S., Darley, R. L., Gilkes, A. F., Goringe, A., Mirza, T. and Burnett, A. K. 1996. In-vivo modelling of myeloid malignancies using severe combined immunodeficient (SCID) mice [Abstract]. British Journal of Haematology 93, pp. 205.

1995

• Darley, R. L., Baines, P., Hoy, T. G. and Burnett, A. K. 1995. Mutant N-RAS induces erythroid lineage dysplasia in human CD34(+) progenitor cells. Blood 86(10), pp. 1665-1665.

1994

• Gallagher, A., Padua, R. A., Alsabah, A., Burnett, A. K. and Darley, R. L. 1994. P21RAS expression in leukemogenesis and hematopoiesis. Blood 84(10), pp. A605-A605.

1992

• Morris, A. G., Darley, R. L. and Bateman, W. J. 1992. The loss of class II MHC antigen expression by ras-transformed murine fibroblasts passaged as tumours correlates with increased tumorigenicity but is not mediated by T cells. Cancer Immunology, Immunotherapy 35(1), pp. 46-52. (10.1007/BF01741054)